RE:PartnershipWith this step cleared with the FDA, the door is wide open for a partnership. The trial is ready to go and Prometic stated that they would be looking at a partner for the phase 3. It is an international trial meaning it is not a cheap trial even if it is simplified so less costly than previously. Also since it will allow both stand alone and combine therapy with ofev, the issue of the trial give a upgrade value for 4050 since it could be a stand alone therapy and become the gold standard if it brings better results than the actual esbriet or ofev therapy (as in the previous study) . I believe potential partners were waiting for this moment to sign a deal and Prometic is also open for a deal at this moment. But as many said, they could also wait for the mid trial readout but the cost to be partner at this moment wont be the same by a multiple factor and once they get to mid term, Prometic won't be so open as today for a partnership if results are stellar. So in my view, a possible deal in the short term is more likely. Since the wednesday presentation is intended for investor and was announce last minute, it is possible to think that a deal would be announce before the presentation to incite the participant to invest in Prometic. IMHO, Eric